Pelthos Therapeutics Inc. (PTHS)
NYSE: PTHS · Biological Products, (No Diagnostic Substances) · Durham, NC · filing with the SEC since 2022
Who owns Pelthos Therapeutics Inc.
As filed with the SECHolders of 5% or more
6
Ligand Pharmaceuticals Incorporated holds 49.9% of Common Stock, par value $0.0001 per share, as its SCHEDULE 13D/A filed Nov 10, 2025 says.
Directors and officers
12
report now, of 14 people on the record since 2024. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 6 named at left.
Holders of 5% or moreshare of the class, as filed
Ligand Pharmaceuticals Incorporated
SCHEDULE 13D/A · filed Nov 10, 2025 · Common Stock, par value $0.0001 per share · 49.9% in Jul 3, 2025
3i, LP
SCHEDULE 13G/A · filed May 7, 2026 · Common Stock, par value $0.0001 per share · 9.9% in Feb 5, 2026
Alexandra Wood (Canada) Inc.
SCHEDULE 13G · filed Jan 15, 2025 · Common Stock, par value $0.0001 per share
Murchinson Ltd.
SCHEDULE 13G · filed Nov 14, 2025 · Common Stock, par value $0.0001 per share
Ezra Friedberg
SCHEDULE 13D/A · filed Jul 3, 2025 · Common Stock, par value $0.0001 per share
Ikarian Capital, LLC
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, par value $0.0001 per share · 8.4% in Feb 17, 2026
AME Equities LLC
SCHEDULE 13G/A · filed Aug 13, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%
What PTHS reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
LNHC, Inc.
A company bought · acquisition · Jun 2025 · owns, named in the 10-K filed Mar 19, 2026
Biofrontera Inc.
A company bought · asset acquisition · owns, named in the 10-K filed Mar 19, 2026
XEGLYZE Asset Purchase Agreement
A company bought · asset acquisition · owns, named in the 10-K filed Mar 19, 2026
Xepi Acquisition
A company bought · asset acquisition · owns, named in the 10-K filed Mar 19, 2026
XEPI Transaction
A company bought · asset acquisition · owns, named in the 10-K filed Mar 19, 2026
3 subsidiaries in 2 countries, from the list filed with the 10-K filed Mar 19, 2026.
Insider tradesForm 4
24sales
2purchases
19sales on a scheduled plan
5people selling
$500,000sold, in dollars
$1.0Mbought, in dollars
Open-market trades on Form 4 from Oct 6, 2025 to Oct 6, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 6, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window6 of 19 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Friedberg Ezra M | director | 11 | $300,000 | 7 | 0 | $0 |
| Greenleaf Peter | director | 5 | $100,000 | 5 | 0 | $0 |
| Pauls Matthew | director | 5 | $100,000 | 5 | 0 | $0 |
| Davis Todd C | director | 0 | $0 | 0 | 2 | $1.0M |
| Francis Knuettel II | CFO, Treas & Secty | 1 | $0 | 0 | 0 | $0 |
| Malamut Richard | director | 2 | $0 | 2 | 0 | $0 |